SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 15, 2024-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, today announced the appointment of Rajiv Patni, M.D., a biopharma industry veteran and global product development expert, to the company’s Board of Directors.

“We are pleased to welcome a proven clinical development leader of Dr. Rajiv Patni’s caliber to our Board of Directors,” said David Lamond, chairperson of Quince’s Board of Directors. “With expertise that spans the continuum from translational to registrational studies and regulatory agency negotiation in several rare diseases, we look forward to his valuable contribution and perspective as the Board supports Quince’s next phase of growth.”

“I am excited to join Quince as it advances its lead asset, EryDex, in a pivotal trial for Ataxia-Telangiectasia and looks ahead to a potential commercial-stage inflection point,” said Dr. Patni. “I also am encouraged by the potential expansion of the company’s proprietary AIDE technology for the treatment of other rare diseases.”

Dr. Patni brings to the Quince Board of Directors nearly 25 years of global product development experience in a diverse set of therapeutic areas, including cardiology, diabetology, hepatology, neurology, and benign hematology. Most recently, he served as Chief Research and Development Officer at Reata Pharmaceuticals, a commercial-stage company recently acquired by Biogen. Previously, Dr. Patni also served as Chief Medical Officer at several successful public, small-cap, and commercial-stage biopharmaceutical companies – Global Blood Therapeutics, Portola Pharmaceuticals, and Adamas Pharmaceuticals. He joined these companies at an inflection point in their R&D growth trajectories and contributed to their acquisition by larger companies. Earlier in his career, Dr. Patni held roles of increasing responsibility at Pfizer, Roche, and Actelion. His proven track record in fostering successful team efforts at these companies contributed to the approval of 11 medicines from the U.S. Food and Drug Administration, European Medicines Agency, and other regulatory agencies. Recent approvals include medicines for several rare diseases, including pulmonary arterial hypertension, advanced Parkinson’s disease, sickle cell disease, and Friedrich’s ataxia. He received his M.D. from the Ichan School of Medicine at Mount Sinai in New York City as part of an accelerated B.S./M.D. program. He completed an internal medicine residency and adult cardiology fellowship at the Albert Einstein College of Medicine, also in New York City, where he continued as an attending physician-scientist before joining the biopharmaceutical industry.

About Quince Therapeutics

Quince Therapeutics (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the potential of a patient’s own biology to deliver innovative and life-changing therapeutics to those living with rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince Therapeutics on social media platforms LinkedIn, Facebook, and Twitter/X.

Forward-looking Statements

Statements in this news release contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements contained in this news release may be identified by the use of words such as “believe,” “may,” “should,” “expect,” “anticipate,” “plan,” “believe,” “estimated,” “potential,” “intend,” “will,” “can,” “seek,” or other similar words. Examples of forward-looking statements include, among others, statements relating to current and future clinical development of EryDex, including in a pivotal trial for Ataxia-Telangiectasia, potential commercial-stage inflection point for EryDex, and expansion of the company’s proprietary autologous intracellular drug encapsulation (AIDE) technology for treatment of other rare diseases. Forward-looking statements are based on Quince’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 14, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240215193487/en/

Media & Investor Contact:
Stacy Roughan
Quince Therapeutics, Inc.
Vice President, Corporate Communications & Investor Relations
ir@quincetx.com

Source: Quince Therapeutics, Inc.